基于甲基化耐受性的功能检测评估MLH1和MSH2基因意义未明变异并识别林奇综合征患者
该研究将MLH1或MSH2变异瞬时表达于MLH1或MSH2缺失的人结直肠癌细胞系(HCT116或LoVo),通过检测细胞对甲基化剂毒性的死亡比例来判断变异是否影响DNA错配修复功能。分析88个变异(验证集40个已分类变异,前瞻集48个意义未明变异),检测正确分类验证集中39/40个变异,并识别出12个影响功能、28个不影响功能的意义未明变异,8个为中间效应无法分类。作者认为该检测可能有助于评估疑似林奇综合征患者中MLH1和MSH2意义未明变异的致病性。
要点
- 该功能检测可正确分类验证集中39/40个已知MLH1或MSH2变异。
- 在前瞻集48个意义未明变异中,检测识别12个影响功能、28个不影响功能,8个为中间效应无法分类。
- 检测结果与根据美国医学遗传学与基因组学学会建议计算的预测评分比较,确认了区分功能受影响与不受影响变异的能力。
核心结论
- 使用测量细胞在甲基化剂诱导DNA损伤后死亡能力的功能检测,可评估MLH1和MSH2变异是否导致DNA错配修复缺陷。
- 该检测可能用于帮助评估疑似林奇综合征患者中MLH1和MSH2意义未明变异的致病性。
研究设计与样本
- 将MLH1或MSH2变异分别瞬时表达于MLH1缺失或MSH2缺失的人结直肠癌细胞系(分别为HCT116或LoVo)。
- 检测原理为错配修复过程导致甲基化损伤DNA碱基的细胞死亡,故测量暴露于甲基化剂后发生死亡细胞的比例,逃逸毒性的细胞被认为携带影响基因产物功能的变异。
- 分析88个变异(主要为错义变异),包括验证集40个既往已分类变异(MLH1 19个、MSH2 21个)和前瞻集48个意义未明变异(MLH1 25个、MSH2 23个)。
- 根据美国医学遗传学与基因组学学会建议,基于临床、体细胞、计算机模拟、人群和功能数据计算所有意义未明变异的预测评分。
主要发现
- 该检测正确分类验证集40个变异中的39个。
- 该检测识别出12个确实改变基因产物功能的意义未明变异和28个不改变功能的意义未明变异;其余8个对错配修复能力有中间效应,无法分类。
- 检测结果与预测评分比较,确认了该检测区分影响基因产物功能与不影响功能的意义未明变异的能力。
局限性
- 8个意义未明变异对错配修复能力有中间效应,无法分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Approximately 75% of patients with suspected Lynch syndrome carry variants in MLH1 or MSH2, proteins encoded by these genes are required for DNA mismatch repair (MMR). However, 30% of these are variants of unknown significance (VUS). A assay that measures cell response to the cytotoxic effects of a methylating agent can determine the effects of VUS in MMR genes and identify patients with constitutional MMR-deficiency syndrome. We adapted this method to test the effects of VUS in MLH1 and MSH2 genes found in patients with suspected Lynch syndrome. METHODS: We transiently expressed MLH1 or MSH2 variants in MLH1- or MSH2-null human colorectal cancer cell lines (HCT116 or LoVo), respectively. The MMR process causes death of cells with methylation-damaged DNA bases, so we measured proportions of cells that undergo death following exposure to the methylating agent; cells that escaped its toxicity were considered to have variants that affect function of the gene product. Using this assay, we analyzed 88 variants (mainly missense variants), comprising a validation set of 40 previously classified variants (19 in MLH1 and 21 in MSH2) and a prospective set of 48 VUS (25 in MLH1 and 23 in MSH2). Prediction scores were calculated for all VUS according to the recommendations of the American College of Medical Genetics and Genomics, based on clinical, somatic, in silico, population, and functional data. RESULTS: The assay correctly classified 39 of 40 variants in the validation set. The assay identified 12 VUS that did alter function of the gene product and 28 VUS that did not; the remaining 8 VUS had intermediate effects on MMR capacity and could not be classified. Comparison of assay results with prediction scores confirmed the ability of the assay to discriminate VUS that affected the function of the gene products from those that did not. CONCLUSIONS: Using an assay that measures the ability of the cells to undergo death following DNA damage induction by a methylating agent, we were able to assess whether variants in MLH1 and MSH2 cause defects in DNA MMR. This assay might be used to help assessing the pathogenicity of VUS in MLH1 and MSH2 found in patients with suspected Lynch syndrome.
引用
- Bouvet D, Bodo S, Munier A, et al. Methylation Tolerance-Based Functional Assay to Assess Variants of Unknown Significance in the MLH1 and MSH2 Genes and Identify Patients With Lynch Syndrome. Gastroenterology. 2019. PMID: 30998989. doi:10.1053/j.gastro.2019.03.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。